Sera Prognostics Reports Q2 2026 Earnings: Revenue Growth Amid Expansion Efforts
In the second quarter of 2026, Sera Prognostics (NASDAQ:SERA) reported revenue of $30 million, a significant increase from $17 million in the same period last year. This growth is attributed to its geographically focused commercialization strategy and early-stage market expansion efforts. The company recorded a net loss of $9.1 million compared to $8.0 million in 2025, primarily driven by increased investments in marketing and commercial activities. Operating expenses rose to $10 million from $9.3 million the previous year due to higher spending on research and development as well as selling, general, and administrative costs. Sera also announced key developments including Illinois Medicaid legislation mandating coverage for proteomic blood tests used to assess preterm birth risk, which could impact approximately 50,000 annual births. The company has exceeded its payer engagement goals across more than 20 states and launched a new partnership program with a national payer in August 2026.
Tickers: $SERA
Topics: cash reserves net loss operating expenses payer expansion revenue